Isaac Melamed1, Roger H Kobayashi2, Maeve O'Connor3, Ai Lan Kobayashi4, Andrew Schechterman5, Melinda Heffron1, Sharon Canterberry4, Holly Miranda1, Nazia Rashid6. 1. IMMUNOe Research Center, Centennial, Colorado, USA. 2. Pediatric Immunology & Allergy, University of California, Los Angeles School of Medicine, Los Angeles, California, USA. 3. Allergy, Asthma & Immunology Relief, Charlotte, North Carolina, USA. 4. Midlands Pediatrics, Papillion, Nebraska, USA. 5. Colorado Neurocognitive Consulting, Centennial, Colorado, USA. 6. Dunwoody Consulting, Ventura, California, USA.
Abstract
Objectives: Pediatric acute-onset neuropsychiatric syndrome (PANS) is a clinical diagnosis in children who have an acute manifestation of varied neuropsychiatric symptoms, including obsessive compulsive disorder, eating disorders, tics, anxiety, irritability, and problems with attention/concentration. PANS may develop as a result of a postinfectious syndrome and may represent a new form of postinfectious autoimmunity. To test the hypothesis that multiple, consecutive infusions of intravenous immunoglobulin (IVIG) for PANS can be efficacious, a multisite, open-label study was designed. Methods: The primary endpoint was evaluation of the efficacy of IVIG [Octagam 5%] in PANS over a period of 6 months (six infusions) based on mean changes in psychological evaluation scores using 6 different assessments, including the Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS), Clinical Global Impression of Severity, and the Parent-Rated Pediatric Acute Neuropsychiatric Symptom Scale (PANS Scale). Results: The final cohort consisted of 21 subjects (7 per site) with moderate to severe PANS. The mean age was 10.86 years (range: 4-16 years). Results demonstrated statistically significant reductions in symptoms from baseline to end of treatment in all six assessments measured. CY-BOCS results demonstrated statistically significant reductions in obsessive compulsive symptoms (p < 0.0001), resulting in >50% improvement sustained for at least 8 weeks after the final infusion and up to 46 weeks in a subset of subjects. Conclusions: In PANS, which may be associated with an underlying immune dysregulation, sequential infusions of IVIG [Octagam 5%] successfully ameliorated psychological symptoms and dysfunction, with sustained benefits for at least 8 weeks, and up to 46 weeks in a subset of subjects. In addition, baseline immune and autoimmune profiles demonstrated significant elevations in a majority of subjects, which requires further evaluation, characterization, and study to clarify the potential immune dysfunction by which PANS manifests and progresses.
Objectives: Pediatric acute-onset neuropsychiatric syndrome (PANS) is a clinical diagnosis in children who have an acute manifestation of varied neuropsychiatric symptoms, including obsessive compulsive disorder, eating disorders, tics, anxiety, irritability, and problems with attention/concentration. PANS may develop as a result of a postinfectious syndrome and may represent a new form of postinfectious autoimmunity. To test the hypothesis that multiple, consecutive infusions of intravenous immunoglobulin (IVIG) for PANS can be efficacious, a multisite, open-label study was designed. Methods: The primary endpoint was evaluation of the efficacy of IVIG [Octagam 5%] in PANS over a period of 6 months (six infusions) based on mean changes in psychological evaluation scores using 6 different assessments, including the Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS), Clinical Global Impression of Severity, and the Parent-Rated Pediatric Acute Neuropsychiatric Symptom Scale (PANS Scale). Results: The final cohort consisted of 21 subjects (7 per site) with moderate to severe PANS. The mean age was 10.86 years (range: 4-16 years). Results demonstrated statistically significant reductions in symptoms from baseline to end of treatment in all six assessments measured. CY-BOCS results demonstrated statistically significant reductions in obsessive compulsive symptoms (p < 0.0001), resulting in >50% improvement sustained for at least 8 weeks after the final infusion and up to 46 weeks in a subset of subjects. Conclusions: In PANS, which may be associated with an underlying immune dysregulation, sequential infusions of IVIG [Octagam 5%] successfully ameliorated psychological symptoms and dysfunction, with sustained benefits for at least 8 weeks, and up to 46 weeks in a subset of subjects. In addition, baseline immune and autoimmune profiles demonstrated significant elevations in a majority of subjects, which requires further evaluation, characterization, and study to clarify the potential immune dysfunction by which PANS manifests and progresses.
Authors: Elena E Perez; Jordan S Orange; Francisco Bonilla; Javier Chinen; Ivan K Chinn; Morna Dorsey; Yehia El-Gamal; Terry O Harville; Elham Hossny; Bruce Mazer; Robert Nelson; Elizabeth Secord; Stanley C Jordan; E Richard Stiehm; Ashley A Vo; Mark Ballow Journal: J Allergy Clin Immunol Date: 2016-12-29 Impact factor: 10.793
Authors: S E Swedo; H L Leonard; M Garvey; B Mittleman; A J Allen; S Perlmutter; L Lougee; S Dow; J Zamkoff; B K Dubbert Journal: Am J Psychiatry Date: 1998-02 Impact factor: 18.112
Authors: Tanya K Murphy; Priyal D Patel; Joseph F McGuire; Allison Kennel; P Jane Mutch; E Carla Parker-Athill; Camille E Hanks; Adam B Lewin; Eric A Storch; Megan D Toufexis; Gul H Dadlani; Carina A Rodriguez Journal: J Child Adolesc Psychopharmacol Date: 2014-10-14 Impact factor: 2.576
Authors: Kiki Chang; Jennifer Frankovich; Michael Cooperstock; Madeleine W Cunningham; M Elizabeth Latimer; Tanya K Murphy; Mark Pasternack; Margo Thienemann; Kyle Williams; Jolan Walter; Susan E Swedo Journal: J Child Adolesc Psychopharmacol Date: 2014-10-17 Impact factor: 2.576
Authors: S J Perlmutter; S F Leitman; M A Garvey; S Hamburger; E Feldman; H L Leonard; S E Swedo Journal: Lancet Date: 1999-10-02 Impact factor: 79.321
Authors: Rosario Trifiletti; Herbert M Lachman; Olivia Manusama; Deyou Zheng; Alberto Spalice; Pietro Chiurazzi; Allan Schornagel; Andreea M Serban; Rogier van Wijck; Janet L Cunningham; Sigrid Swagemakers; Peter J van der Spek Journal: Sci Rep Date: 2022-06-30 Impact factor: 4.996